Amarillo Biosciences Publishes Reviews on Oral Interferon
Amarillo Biosciences, Inc. (ABI) has recently published review papers in an effort to motivate international discussion of low dose interferon lozenges as a therapy for many diseases, including influenza. A review entitled "Systemic effects of interferons after oral administration in animals and humans" was published in the American Journal of Veterinary Research, Volume 66, No. 1, January 2005, pages 164-172. This review contains 200 citations of reports of the systemic beneficial action of orally delivered interferon in dogs, cats, horses, swine, cattle, poultry, rats, mice, Guinea pigs and humans.
Recent statements from the World Health Organization (WHO) have warned that the ongoing epidemic of avian influenza may be the start of the next human influenza pandemic. Such pandemics occurred in 1918-1919, 1957 and 1968. Influenza experts are concerned that a new pandemic could kill millions of people. A review of the literature reveals that Soviet, Bulgarian and Japanese clinicians published in the late 1960's and 1970's that low doses of interferon given intranasally or orally significantly reduced the illness rate and mortality due to influenza. Such claims were rejected by Western experts because the low purity of interferon at that time and skepticism that low doses could be beneficial when high doses tested in the West were not particularly beneficial.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
